Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05827978 · ClinicalTrials.gov registry record · Phase 3
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
A Phase 3 study, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 3
- Development phase
- 8,411
- Enrollment target
NCT05827978: Completed Phase 3 study, sponsored by ModernaTX.
NCT05827978 is a Phase 3 study that has completed, run by ModernaTX. The registered enrollment target is 8,411 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (991% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05827978, a Phase 3 study, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8,411 participants
- Enrollment target
Study Summary
This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults.
Primary Outcome
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria and Yamagata strains. Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were converted to the ULOQ.
Interventions
- BIOLOGICAL mRNA-1010
- BIOLOGICAL Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,411 participants |
| Start Date | 2023-04-17 |
| Est. Completion | 2024-06-24 |
| Phase | Phase 3 |
What the finished NCT05827978 record still lists
NCT05827978 is an interventional study that assigns participants to a tested intervention. Its 8,411 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (991% higher).
The record links to 0 conditions, and to 2 interventions - of which mRNA-1010 is the first listed.
NCT05827978 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05827978 about?
NCT05827978 is a clinical study titled "Study of mRNA-1010 Seasonal Influenza Vaccine in Adults". This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults.
What is the current status of trial NCT05827978?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8,411 participants. The study started on 2023-04-17. Estimated completion is 2024-06-24.
What interventions are being tested in trial NCT05827978?
The interventions under investigation include: mRNA-1010 (BIOLOGICAL), Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05827978?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05827978's enrollment target sits among peer trials
8,411 32nd of 2000 higher than 1,969 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07185828 · 8,286 participants · NA
Informing Low-acuity Emergency Department Patients of Non-emergent Resources (2)
- NCT06098079 · 8,600 participants · Phase 4
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
- NCT06435806 · 8,200 participants · NA
Medical Illustration Design Characteristic Evaluation
- NCT06058234 · 8,680 participants
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI